{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34711920",
  "DateCompleted": {
    "Year": "2022",
    "Month": "03",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "06"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "10",
        "Day": "28"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41385-021-00464-w"
    ],
    "Journal": {
      "ISSN": "1935-3456",
      "JournalIssue": {
        "Volume": "15",
        "Issue": "2",
        "PubDate": {
          "Year": "2022",
          "Month": "Feb"
        }
      },
      "Title": "Mucosal immunology",
      "ISOAbbreviation": "Mucosal Immunol"
    },
    "ArticleTitle": "Immune interventions in COVID-19: a matter of time?",
    "Pagination": {
      "StartPage": "198",
      "EndPage": "210",
      "MedlinePgn": "198-210"
    },
    "Abstract": {
      "AbstractText": [
        "As the COVID-19 pandemic is still ongoing, and considering the lack of efficacy of antiviral strategies to this date, and the reactive hyperinflammation leading to tissue lesions and pneumonia, effective treatments targeting the dysregulated immune response are more than ever required. Immunomodulatory and immunosuppressive drugs have been repurposed in severe COVID-19 with contrasting results. The heterogeneity in the timing of treatments administrations could be accountable for these discrepancies. Indeed, many studies included patients at different timepoints of infection, potentially hiding the beneficial effects of a time-adapted intervention. We aim to review the available data on the kinetics of the immune response in beta-coronaviruses infections, from animal models and longitudinal human studies, and propose a four-step model of severe COVID-19 timeline. Then, we discuss the results of the clinical trials of immune interventions with regards to the timing of administration, and finally suggest a time frame in order to delineate the best timepoint for each treatment."
      ],
      "CopyrightInformation": "\u00a9 2021. The Author(s), under exclusive licence to Society for Mucosal Immunology."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Bic\u00eatre, Assistance publique des h\u00f4pitaux de Paris, GHU Paris-Saclay, Le Kremlin Bic\u00eatre, France. leoplacais@gmail.com."
          },
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 Paris-Saclay, Inserm, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes ImVA, UMR Inserm U1184, 94270, Le Kremlin Bic\u00eatre, France. leoplacais@gmail.com."
          }
        ],
        "LastName": "Pla\u00e7ais",
        "ForeName": "L\u00e9o",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de maladies infectieuses, H\u00f4pital Saint Antoine, Assistance publique des h\u00f4pitaux de Paris, Paris, France. ohermine@gmail.com."
          },
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Paris, Paris, France. ohermine@gmail.com."
          }
        ],
        "LastName": "Richier",
        "ForeName": "Quentin",
        "Initials": "Q"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de M\u00e9decine Interne et Immunologie Clinique, H\u00f4pital Bic\u00eatre, Assistance publique des h\u00f4pitaux de Paris, GHU Paris-Saclay, Le Kremlin Bic\u00eatre, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 Paris-Saclay, Inserm, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes ImVA, UMR Inserm U1184, 94270, Le Kremlin Bic\u00eatre, France."
          }
        ],
        "LastName": "No\u00ebl",
        "ForeName": "Nicolas",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de maladies infectieuses, H\u00f4pital Saint Antoine, Assistance publique des h\u00f4pitaux de Paris, Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Sorbonne Universit\u00e9, Inserm IPLESP, Paris, France."
          }
        ],
        "LastName": "Lacombe",
        "ForeName": "Karine",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de rhumatologie, H\u00f4pital Bic\u00eatre, Assistance publique des h\u00f4pitaux de Paris, Le Kremlin Bic\u00eatre, France."
          }
        ],
        "LastName": "Mariette",
        "ForeName": "Xavier",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Paris, Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Service d'h\u00e9matologie, H\u00f4pital Necker, Assistance publique des h\u00f4pitaux de Paris, Paris, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Institut Imagine, INSERM U1163, Paris, France."
          }
        ],
        "LastName": "Hermine",
        "ForeName": "Olivier",
        "Initials": "O"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Mucosal Immunol",
    "NlmUniqueID": "101299742",
    "ISSNLinking": "1933-0219"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunomodulating Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "immunology",
        "therapy",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Administration Schedule"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Immunomodulating Agents"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "L.P. and Q.R. did not receive any grants or fees. N.N. reports personal fees from BIOGEN, BMS and Janssen. K.L. reports grants, personal fees, and non-financial support from, MSD; non-financial support and personal fees from Gilead, Janssen and Abbvie; and personal fees from ViiV Healthcare. O.H. reports grants from Celgene, Alexion, AB Science, and Inatherys. X.M. reports grant from Ose and personal fees from BMS, GSK, Janssen, Pfizer, Sanofi and UCB."
}